{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:49:41Z","timestamp":1761569381006,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clgc.2022.06.011","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T02:18:24Z","timestamp":1655173104000},"page":"591-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["BCG Administration after Prior Radiation Treatment for Prostate Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Adri M.","family":"Durant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kassem S.","family":"Faraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.06.011_bib0001","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA. Cancer J. Clin"},{"key":"10.1016\/j.clgc.2022.06.011_bib0002","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma In Situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0003","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Sam S","year":"2016","journal-title":"J. Urol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0004","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/cncr.29841","article-title":"Therapeutic radiation and the potential risk of second malignancies","volume":"122","author":"Kamaran","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.06.011_bib0006","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2022.06.011_bib0007","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.urolonc.2012.04.006","article-title":"The characteristics of bladder cancer after radiotherapy for prostate cancer","volume":"31","author":"Abern","year":"2013","journal-title":"Urol. Oncol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0008","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur. Urol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.juro.2007.08.157","article-title":"Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy","volume":"179","author":"Bostrom","year":"2008","journal-title":"J. Urol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000356115","article-title":"Radiation-induced secondary malignancy in prostate cancer: a systematic review and meta-analysis","volume":"93","author":"Jin","year":"2014","journal-title":"Urol. Int"},{"key":"10.1016\/j.clgc.2022.06.011_bib0011","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1470-2045(03)01191-4","article-title":"Effects of radiation on normal tissue: consequences and mechanisms","volume":"4","author":"Stone","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0012","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fonc.2013.00073","article-title":"Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk","volume":"3","author":"Braunstein","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0013","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.urology.2010.01.048","article-title":"Radical cystectomy in patients previously treated for localized prostate cancer","volume":"76","author":"Jayram","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2022.06.011_bib0014","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.juro.2010.01.014","article-title":"Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer","volume":"183","author":"Yee","year":"2010","journal-title":"J. Urol"},{"key":"10.1016\/j.clgc.2022.06.011_bib0015","doi-asserted-by":"crossref","unstructured":"Pisters LL, Tykochinsky G, Wajsmant Z. Intravesical bacillus calmette-guerin or mitomycin c in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. 146, 1514\u20131517 (1991).","DOI":"10.1016\/S0022-5347(17)38154-5"},{"key":"10.1016\/j.clgc.2022.06.011_bib0016","first-page":"857","article-title":"Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer","volume":"31","author":"Rao","year":"2013","journal-title":"Urol. Oncol. Semin. Orig. Investig"},{"key":"10.1016\/j.clgc.2022.06.011_bib0017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1464-410x.1999.00971.x","article-title":"Intravesical bacille Calmette-Guerin in the treatment of carcinoma in situ or high-grade superficial bladder carcinoma after radiotherapy for bladder carcinoma","volume":"83","author":"Palou","year":"1999","journal-title":"BJU Int"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:26Z","timestamp":1761564926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1558767322001379"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCG Administration after Prior Radiation Treatment for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}